NEW YORK (Reuters) - Large investors in U.S. biotech companies are likely to capture serious windfall profits as deal activity picks up in the sector. A Reuters analysis of investors' average cost found that six U.S. biotech companies flagged as potential takeover targets could yield billions of dollars in profits for their major shareholders at current share prices. Ownership of these companies is dominated by a handful of institutional investors, such as Wellington Management, Fidelity Management & Research, Capital Group Cos and T Rowe Price Associates. ...
via Health News Headlines - Yahoo! News Read More Here..
No comments:
Post a Comment